|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006141,
umls-concept:C0006142,
umls-concept:C0060133,
umls-concept:C0079459,
umls-concept:C0178602,
umls-concept:C0210630,
umls-concept:C0240951,
umls-concept:C0439185,
umls-concept:C0600688,
umls-concept:C1257890,
umls-concept:C1516213,
umls-concept:C1521721,
umls-concept:C1522673,
umls-concept:C1527178,
umls-concept:C1705938,
umls-concept:C2603343,
umls-concept:C2717829
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-9-10
|
|
pubmed:abstractText |
Conventional dosages of cytostatics in mg/m2 will cause marked variations in systemic exposure, resulting in over- and under-treatment, at least with respect to side effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
403-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9636831-Aged,
pubmed-meshheading:9636831-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9636831-Breast Neoplasms,
pubmed-meshheading:9636831-Chemotherapy, Adjuvant,
pubmed-meshheading:9636831-Cyclophosphamide,
pubmed-meshheading:9636831-Dose-Response Relationship, Drug,
pubmed-meshheading:9636831-Drug Administration Schedule,
pubmed-meshheading:9636831-Epirubicin,
pubmed-meshheading:9636831-Female,
pubmed-meshheading:9636831-Fluorouracil,
pubmed-meshheading:9636831-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9636831-Hematologic Diseases,
pubmed-meshheading:9636831-Humans,
pubmed-meshheading:9636831-Mastectomy, Radical,
pubmed-meshheading:9636831-Middle Aged,
pubmed-meshheading:9636831-Prognosis,
pubmed-meshheading:9636831-Recombinant Proteins,
pubmed-meshheading:9636831-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
|
|
pubmed:affiliation |
Department of Oncology, Akademiska sjukhuset, Uppsala, Sweden. jonas.bergh@oncology.uu.se
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
